Compounded GLP-1 Rules in 2026: What Changed and What It Means

Compounded semaglutide and tirzepatide became widely available because of a specific legal mechanism: when a drug is on the FDA shortage list, compounding pharmacies may make copies of it. Those shortages have been resolved, and the FDA has since moved to close the remaining pathways. This is what actually changed, what is still permitted, and what it means for patients currently on a compounded GLP-1.

How Compounded GLP-1s Became Legal in the First Place

U.S. law generally prohibits compounding pharmacies from producing copies of commercially available FDA-approved drugs. There is a carve-out: when a drug appears on the FDA shortage list, that restriction relaxes so patients are not left without therapy.

Semaglutide and tirzepatide both entered shortage as demand outran manufacturing capacity. That triggered the exemption, and an entire telehealth industry grew on top of it — offering compounded versions at a fraction of brand pricing. Two distinct facility categories were involved:

• 503A pharmacies — traditional compounding pharmacies preparing medications for individually identified patients pursuant to a prescription.
• 503B outsourcing facilities — larger operations registered with the FDA that may produce in bulk, without patient-specific prescriptions, under stricter manufacturing standards.

The Regulatory Timeline

What the 503B Bulks List Proposal Actually Does

The 503B bulks list governs which bulk drug substances outsourcing facilities may use. The FDA proposal would remove semaglutide, tirzepatide, and liraglutide from consideration, on the finding that there is no clinical need for outsourcing facilities to compound them now that approved products are available in adequate supply.

Read precisely, this is a narrowing of large-scale compounding rather than a blanket prohibition. Pharmacy policy analysts have characterized it as closing the industrial-scale pathway while leaving a much smaller 503A route intact for genuinely patient-specific circumstances — for example, a documented clinical need for a formulation or dose that the approved product cannot provide.

Enforcement Beyond Compounding Rules

The pressure has not come only from drug-manufacturing rules. Several parallel actions have targeted how these products are marketed:

• FDA warning letters — a batch issued to 25 telehealth companies over false and misleading claims in their advertising.
• FTC enforcement — action against telemedicine company NextMed over allegations of misleading pricing, fake reviews, and deceptive practices, followed by a final order.
• National Advertising Division decisions — self-regulatory rulings pressing compounded GLP-1 advertisers to substantiate claims.
• Manufacturer litigation — Novo Nordisk and Eli Lilly have pursued legal action against compounders and telehealth sellers.

The practical signal for patients: aggressive marketing claims in this category now carry regulatory risk for the seller, which is a useful heuristic when evaluating a provider. Our guidance on evaluating compounding pharmacies covers the quality signals that matter.

Why Compounded Products Are Still Widely Advertised

Reporting through mid-2026 found compounded Ozempic and Zepbound analogues still widely available despite the shortages ending. Several factors explain the gap between rule and reality: enforcement takes time and resources, litigation has created uncertainty about timelines, some sellers have shifted to personalized-dosing framing, and others operate outside the regulated system entirely.

Availability is not a reliable indicator of legality or quality. Court decisions could still affect enforcement timelines, so the situation remains genuinely unsettled.

What Patients on Compounded GLP-1s Should Do

Do not stop abruptly on your own. Discontinuing a GLP-1 without a plan typically leads to appetite rebound and weight regain. Talk to your prescriber before changing anything.

Re-examine the cost comparison — it has changed. The core argument for compounded GLP-1s was price. That gap has narrowed considerably:

• Foundayo (orforglipron) starts around $149/month self-pay, with $50/month for eligible Medicare Part D beneficiaries from July 2026
• Manufacturer direct channels — LillyDirect and NovoCare — offer discounted cash pricing on approved products
• Some telehealth platforms now bundle brand-name access at competitive rates

For a growing number of patients, an FDA-approved product is now within range of what they were paying for a compounded one — with verified identity, potency, and sterility, and without regulatory uncertainty.

Vet any provider still offering compounded products. Ask which facility type prepares the medication, whether third-party potency and sterility testing is performed, and what the legal basis for compounding is now that shortages have resolved. A provider that cannot answer clearly is a provider to avoid.

A Note on Gray-Market Peptides

As regulated compounding narrows, some patients migrate to unregulated sellers marketing "research peptides." The FDA has warned companies illegally selling unapproved products containing semaglutide, tirzepatide, retatrutide, survodutide, or mazdutide. These are not compounded medications prepared under pharmacy oversight — they are unapproved drugs of unverified identity, purity, sterility, and dose, often sold with a nominal disclaimer that they are not for human use.

This is a categorically different risk from a licensed compounding pharmacy operating in a contested regulatory space, and it is not a reasonable substitute for either.

The Bottom Line

The compounded GLP-1 era is closing, deliberately. Shortage-based compounding has ended, the FDA has proposed removing these molecules from the 503B bulks list, and enforcement has extended to advertising practices. A narrow 503A pathway survives for genuine patient-specific need, and litigation may still shift timelines.

The more useful development for most patients is that the price argument has weakened on its own. With approved oral GLP-1s starting near $149/month and manufacturer direct channels discounting brand products, the trade-off that once favored compounded medication no longer clearly does. Revisit that math with your prescriber rather than assuming the answer you reached in 2024 still holds.